Drug details

Steglatro (ertugliflozin tablets for oral use)

type of Antidiabetics, SGLT2 Inhibitors

Steglatro (ertugliflozin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• nausea,
• vomiting,
• fever,
• lightheadedness,
• confusion,
• stomach pain,
• dizziness,
• weakness,
• little or no urination,
• increased urination,
• trouble breathing,
• unusual drowsiness,
• pain or burning when you urinate,
• feeling unwell,
• tenderness,
• blood in your urine, and
• pain in your pelvis or back
• new pain,
• sores,
• ulcers,
• infections in your legs or feet,

The following drugs are related to Steglatro, either as a replacement or used together:

• Brenzavvy (bexagliflozin tablets)
• Zegalogue (dasiglucagon injection)